Angiogenesis

Annual Review of Medicine

Volumn 57, Issue , 2006, Pages 1-18

  Folkman, Judah ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenesis inhibitors; Avastin; Caplostatin; Endogenous angiogenesis inhibitors; Endostatin; Tumor dormancy; U shaped curve

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPLOSTATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENDOSTATIN; ERLOTINIB; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; MERCAPTOPURINE; PEGAPTANIB; THALIDOMIDE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CLINICAL RESEARCH; COLORECTAL CANCER; DRUG POTENTIATION; FOOD AND DRUG ADMINISTRATION; HUMAN; LUNG CANCER; MULTIPLE MYELOMA; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; REVIEW; UNITED STATES;

ANGIOGENESIS INHIBITORS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES;

EID: 32944463899     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.57.121304.131306     Document Type: Review

References (101)

1. Folkman J. 1971. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285:1182-86
2. Folkman J. 1998. Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence. Endocrinology 139:441-42
3. Rupnick MA, Panigrahy D, Zhang CY, et al. 2002. Adipose tissue mass can be regulated through the vasculature. Proc. Natl. Acad. Sci. USA 99:10730-35
4. Black WC, Welch HG. 1993. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N. Engl. J. Med. 328:1237-43
5. Folkman J, Kalluri R. 2004. Cancer without disease. Nature 427:787
6. Folkman J. 2004. Endogenous angiogenesis inhibitors. Acta Pathol. Microbiol. Immunol. Scan. 112:496-507
7. Nyberg P, Xie L, Kalluri R. 2005. Endogenous inhibitors of angiogenesis. Cancer Res. 65:3967-79
8. Ezzell C. 1998. Starving tumors of their lifeblood. Sci. Am. 279:33-34
9. Bishop JM. 1985. Viral oncogenes. Cell 42:23-38
10. Felsher DW, Bishop JM. 1999. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell. 4:199-207
11. Chin L, Tam A, Pomerantz J, et al. 1999. Essential role for oncogenic Ras in tumour maintenance. Nature 400:468-72
12. Gimbrone MA Jr, Leapman SB, Cotran RS, et al. 1972. Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 136:261-76
13. Brem S, Brem H, Folkman J, et al. 1976. Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res. 36:2807-12
14. Holmgren L, O'Reilly MS, Folkman J, 1995. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1:149-53
15. Hanahan D, Folkman J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-64
16. Arbiser JL, Moses MA, Fernandez CA, et al. 1997. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc. Natl. Acad. Sci. USA 94:861-66
17. Folkman J. 2000. Incipient angiogenesis. J. Natl. Cancer Inst. 92:94-95
18. Achilles EG, Fernandez A, Allred EN, et al. 2001. Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for "no take" of human tumors in mice. J. Natl. Cancer Inst. 93:1075-81
19. Udagawa T, Fernandez A, Achilles EG, et al. 2002. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J. 16:1361-70
20. Watnick RS, Cheng Y-N, Rangarajan A, et al. 2003. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 3:219-31
21. Streit M, Riccardi L, Velasco P, et al. 1999. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc. Natl. Acad. Sci. USA 96:14888-93
22. 21a. Fernandez A, Udagawa T, Schwesinger C, et al. 2001. Angiogenic potential of prostate carcinoma cells overexpressing Bcl-2. J. Natl. Cancer Inst. 93:208-13
23. Brouty-Boye D, Zetter BR. 1980. Inhibition of cell motility by interferon. Science 208:516-18
24. Dvorak HF, Gresser I. 1989. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J. Natl. Cancer Inst. 81:497-502
25. Sidky YA, Borden EC. 1987. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular diseases. Cancer Res. 47:5155-61
26. Taylor S, Folkman J. 1982. Protamine is an inhibitor of angiogenesis. Nature 297:307-12
27. Crum R, Szabo S, Folkman J. 1985. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 230:1375-78
28. Ingber D, Fujita T, Kishimoto S, et al. 1990. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348:555-57
29. O'Reilly MS, Holmgren L, Shing Y, et al. 1994. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-28
30. O'Reilly MS, Boehm T, Shing Y, et al. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-85
31. Boehm T, Folkman J, Browder T, et al. 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-7
32. Maeshima Y, Colorado PC, Torre A, et al. 2000. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J. Biol. Chem. 275:21340-48
33. Dameron KM, Volpert OV, Tainsky MA, et al. 1994. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-84
34. Zhang L, Yu D, Hu M, et al. 2000. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res. 60:3655-61
35. Sherif ZA, Nakai S, Pirollo KF, et al. 2001. Downmodulation of bFGF-binding protein expression following restoration of p53 function. Cancer Gene Ther. 8:771-82
36. Ravi R, Mookerjee B, Bhujwalla ZM, et al. 2000. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14:34-44
37. Sund M, Hamano Y, Sugimoto H, et al. 2005. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc. Natl. Acad. Sci. USA 102:2934-39
38. Zorick TS, Mustacchi Z, Bando SY, et al. 2001. High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours. Eur. J. Hum. Genet. 9:811-14
39. Yang Q, Rasmussen SA, Friedman JM. 2002. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 359:1019-25
40. Fulcher T, Griffin M, Crowley S, et al. 1998. Diabetic retinopathy in Down's syndrome. Br. J. Ophthalmol. 82:407-9
41. Chadefaux B, Ceballos I, Hamet M, et al. 1988. Is absence of atheroma in Down syndrome due to decreased homocysteine levels? Lancet 2:741
42. Moulton KS, Heller E, Konerding MA, et al. 1999. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 99:1726-32
43. Moulton KS, Olsen BR, Sonn S, et al. 2004. Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis. Circulation 110:1330-36
44. Zeng X, Chen J, Miller YI, et al. 2005. Endostatin binds biglycan and LDL and interferes with LDL retention to subendothelial matrix during atherosclerosis. J. Lipid Res. 46(9):1849-59
45. Ferrara N. 2004 Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25:581-611
46. Relf M, LeJeune S, Scott PA, et al. 1997. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57:963-69
47. Folkman J. 2004. Angiogenesis in breast cancer. In The Breast: Comprehensive Management of Benign and Malignant Disorders, ed. KI Bland, EM Copeland III, pp. 563-86. St. Louis: Saunders
48. Satchi-Fainaro R, Puder M, Davies JW, et al. 2004. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med. 10:255-61
49. Satchi-Fainaro R, Mamluk R, Wang L, et al. 2005. Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 7:251-61
50. Milkowski DM, Weiss RA. 1999. TNP-470. In Antiangiogenic Agents in Cancer Therapy, ed. BA Teicher, pp. 385-98. Totowa, NJ: Humana
51. Griffith EC, Su Z, Turk BE, et al. 1997. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem. Biol. 4:461-71
52. Wen W, Moses MA, Wiederschain D, et al. 1999. The generation of endostatin is mediated by elastase. Cancer Res. 59:6052-56
53. Felbor U, Dreier L, Bryant RA, et al. 2000. Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J. 19:1187-94
54. Ding YH, Javaherian K, Lo KM, et al. 1998. Zinc-dependent dimers observed in crystals of human endostatin. Proc. Natl. Acad. Sci. USA 95:10443-48
55. Blackhall FH, Merry CL, Lyon M, et al. 2003. Binding of endostatin to endothelial heparan sulphate shows a differential requirement for specific sulphates. Biochem. J. 375:131-39
56. Wickstrom SA, Alitalo K, Keski-Oja J. 2002. Endostatin associates with integrin alpha 5 beta 1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res. 62:5580-89
57. Sudhakar A, Sugimoto H, Yang C, et al. 2003. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc. Natl. Acad. Sci. USA 100:4766-71
58. Tjin Tham Sjin RM, Satchi-Fainaro R, Birsner AE, et al. 2005. A 27-amino-acid synthetic peptide corresponding to the NH2-terminal zinc-binding domain of endostatin is responsible for its antitumor activity. Cancer Res. 65:3656-63
59. Folkman J, Kalluri R. 2003. Tumor angiogenesis. In Cancer Medicine, ed. DW Kufe, RE Pollock, RR Weichselbaum, et al., pp. 161-94. Hamilton, Ontario: B.C. Decker
60. Kisker O, Becker CM, Prox D, et al. 2001. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 61:7669-74
61. Celik I, Sürücü O, Dietz C, et al. 2005. Therapeutic efficacy of endostatin exhibits a bi-phasic dose response curve. Cancer Res. In press
62. Slaton JW, Perrotte P, Inoue K, et al. 1999. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res. 5:2726-34
63. Panigrahy D, Singer S, Shen LQ, et al. 2002. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J. Clin. Invest. 110:923-32
64. Tjin Tham Sjin RM, Naspinski J, Birsner AE, et al. 2005. Endostatin therapy reveals a U-shaped curve for anti-tumor activity. Mol. Ther. In press
65. Feldman AI, Alexander HR, Hewitt SM, et al. 2001. Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. J. Natl. Cancer Inst. 93:1014-20
66. Yamanaka R, Zullo SA, Ramsey J, et al. 2001. Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus. Cancer Gene Ther. 8:796-802
67. Eisterer W, Jiang X, Bachelot T, et al. 2002. Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. Mol. Ther. 5:352-59
68. Kuo CJ, Farnebo F, Yu EY, et al. 2001. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc. Natl. Acad. Sci. USA 98:4605-10
69. Abdollahi A, Hahnfeldt P, Maercker C, et al. 2004. Endostatin's antiangiogenic signaling network. Mol. Cell 13:649-63
70. Shichiri M, Hirata Y. 2001. Antiangiogenesis signals by endostatin. FASEB J. 15:1044-53
71. Knies-Banforth UE, Fox SB, Poulsom R, et al. 2004. c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular growth factor-dependent mechanism. Cancer Res. 64:6563-70
72. Browder T, Butterfield CE, Kraling BM, et al. 2000. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60:1878-86
73. Klement G, Baruchel S, Rak J, et al. 2000. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105:R15-24
74. Hamano Y, Sugimoto H, Soubasakos MA, et al. 2004. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 64:1570-74
75. Bocci G, Francia G, Man S, et al. 2003. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc. Natl. Acad. Sci. USA 100:12917-22
76. Hanahan D, Bergers G, Bergsland E. 2000. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105:1045-47
77. Kerbel RS, Kaman BA. 2004. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4:423-30
78. Lyden D, Hattori K, Dias S, et al. 2001. Impaired recruitment of bone marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7:1194-1201
79. Rohan RM, Fernandez A, Udagawa T, et al. 2000. Genetic heterogeneity of angiogenesis in mice. FASEB J. 14:871-76
80. Shaked Y, Bertolini F, Man S, et al. 2005. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7:101-11
81. Rogers MS, D'Amato RJ. 2005. The effect of genetic diversity on angiogenesis. Exp. Cell Res. In press
82. Menzel O, Bekkeheien RC, Raymond A, et al. 2004. Knobloch syndrome: novel mutations in COL18A1, evidence for genetic heterogeneity and a functionally impaired polymorphism in endostatin. Hum. Mutat. 23:77-84
83. Vasku V, Vasku A, Tschoplova S, et al. 2002. Genotype association of C(-735)T polymorphism in matrix metalloproteinase 2 gene with G(8002)A endothelin 1 gene with plaque psoriasis. Dermatology 204:262-65
84. Brouillard P, Boon LM, Mulliken JB, et al. 2002. Mutations in a novel factor glomulin, are responsible for glouvenous malformations ("glomangiomas"). Am. J. Hum. Genet. 70:866-74
85. Tian XL, Kadaba R, You SA, et al. 2004. Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome. Nature 427:640-45
86. Karkkainen MJ, Ferrell RE, Lawrence EC. et al. 2000. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat. Genet. 25:153-59
87. Hurwitz H, Fehrenbacher K, Novotny W, et al. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350:2335-42
88. D'Amato RJ, Loughnan MS, Flynn E, et al. 1994. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA 91:4082-85
89. Gelati M, Corsini E, Frigerio S, et al. 2003. Effects of thalidomide on parameters involved in angiogenesis: an in vitro study. J. Neurooncol. 64:193-201
90. Yabu T, Tomimoto H, Yamoaka S, et al. 2005. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood 106:125-34
91. Ginns LC, Roberts DH, Mark EJ, et al. 2003. Pulmonary capillary hemangiomatosis with atypical endotheliomatosis: successful antiangiogenic therapy with doxycycline. Chest 124:2017-22
92. Kaban LB, Mulliken JB, Ezekowitz RA, et al. 1999. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics 103:1145-49
93. Marler JJ, Rubin JB, Trede NS, et al. 2002. Successful antiangiogenic therapy of giant cell angioblastoma with interferon alpha 2b: report of 2 cases. Pediatrics 109:E37
94. Kieran MW, Turner C, Rubin J, et al. 2005. A feasibility trial of anti-angiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J. Ped. Hematol. Oncol. 27:573-81
95. Li VW, Ball RA, Vassan N, et al. 2005. Antiangiogenic therapy of squamous cell carcinoma using combinatorial agents. J. Clin. Oncol. 23(16s) (Abstr. 3032)
96. Folkman J. 2003. Angiogenesis. In Targeted Therapies in Rheumatology, ed. JS Smolen, PE Lipsky, pp. 111-31. London/New York: Martin Dunitz
97. Nagashima M, Asano G, Yoshino S. 2000. Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. J. Rheumatol. 27:2339-42
98. Roy R, Wewer UM, Zurakowski D, et al. 2004. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J. Biol. Chem. 279:51323-30
99. Klement G, Kikuchi L, Kieran M, et al. 2004. Early tumor detection using platelet uptake of angiogenesis regulators. Blood 104:239a (Abstr. 839)
100. Heymach J, Kulke MH, Fuchs CS, et al. 2003. Circulating endothelial cells as a surrogate marker of antiangiogenic activity in patients treated with endostatin. Proc. Am. Soc. Clin. Oncol. 22:244 (Abstr. 979)
101. Hamano Y, Zeisberg M, Sugimoto H, et al. 2003. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV-beta3 integrin. Cancer Cell 3:589-601